NEK11: A Potential Drug Target and Biomarker for Serine/Threonine-Protein Kinase Nek11

Target Name: NEK11

NCBI ID: G79858

NEK11

NEK11: A Potential Drug Target and Biomarker for Serine/Threonine-Protein Kinase Nek11

Serine/threonine-protein kinase (S/TP kinase) Nek11 is a key regulator of cell signaling pathways, including the T-cell receptor signaling pathway. The Nek11 kinase is highly conserved across various species, and its study has provided valuable insights into the mechanisms of cell signaling. Nek11 has also been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, it is a promising target for drug development.

The Nek11 gene is located on chromosome 18q21 and encodes a 21-kDa protein that plays a critical role in regulating cell signaling pathways. The Nek11 protein is composed of two distinct domains: a N-terminal transmembrane domain and a C-terminal catalytic domain. The N-terminal domain is responsible for Nek11's ability to interact with its downstream signaling molecules, while the C-terminal domain is responsible for the kinase's catalytic activity.

Nek11 has been shown to play a critical role in regulating various cellular processes, including cell growth, differentiation, and survival. For example, Nek11 has been shown to promote the growth and survival of cancer cells, and it has been proposed as a potential therapeutic target for cancer treatment. Additionally, Nek11 has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Despite the potential benefits of targeting Nek11, the kinase has also been shown to contribute to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, Nek11 has been shown to promote the growth and survival of cancer cells and has been implicated in the development of neurodegenerative diseases. Additionally, Nek11 has been implicated in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Given the potential benefits and risks of targeting Nek11, researchers have been actively searching for small molecules that can inhibit Nek11 activity. One class of compounds that have been shown to inhibit Nek11 activity are the aryl hydrocarbon receptor (AhR) antagonists. These compounds have been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another class of compounds that have been shown to inhibit Nek11 activity are the protein kinase C (PKC) inhibitors. These compounds have been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to small molecules and PKC inhibitors, researchers have also been exploring the use of drugs that can interact with Nek11 directly. One such drug is an oral small molecule called Y-27632, which is a potent inhibitor of Nek11 activity. Y-27632 has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

While the use of Y-27632 may be an effective treatment for certain diseases, there are also concerns about its potential side effects. As such, researchers are actively searching for drugs that can interact with Nek11 and its downstream signaling pathways in a more targeted and beneficial way.

In conclusion, NEK11 is a serine/threonine-protein kinase that plays a critical role in regulating cell signaling pathways, including the T-cell receptor signaling pathway. Despite its potential benefits, NEK11 has also been shown to contribute to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, NEK11 is an attractive target for drug development, and various classes of compounds, including small molecules and PKC inhibitors, have been shown to be effective in inhibiting Nek11 activity. Further research is needed to fully understand the effects of these compounds

Protein Name: NIMA Related Kinase 11

Functions: Protein kinase which plays an important role in the G2/M checkpoint response to DNA damage. Controls degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is required for BTRC-mediated polyubiquitination and degradation

The "NEK11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEK11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets